Finally, to demonstrate the role of MVs in the transfer of pMHC-I from activated immune cells to cancer cells and in activating CD8+ lymphocytes, we treated CT26.WT cells with different amounts of MVs secreted from activated T2Kb cells pre-incubated with or without pOVA. This evidence concerns the gene CD8A and cancer.